Decision to list medical devices supplied by Baxter Healthcare Limited

Hospital devices

Decision

We are pleased to announce the approval of a listing agreement with Baxter Healthcare Limited for the supply of haemodialysis equipment and products to DHBs.

In summary this will result in:

  • Baxter’s products being listed in Part III of Section H of the Pharmaceutical Schedule from 1 August 2020 under a national agreement that all DHBs may purchase under (“Agreement”); and
  • DHBs being able to continue to purchase other suppliers’ brands of haemodialysis equipment and products.

Any changes to the original proposal?

This decision was subject to a consultation letter dated 12 February 2020 and then a second round of consultation with DHB stakeholders which was released on 5 June 2020.

Missing products were added to the listing, conditions around installation of equipment and tools for commercial calculations were updated in response to feedback from our first round of consultation.

Only minor amendments have been made to the commercial tools following the second round of consultation.

Who we think will be most interested

  • DHB staff:
    • Haemodialysis staff
    • Procurement managers
  • Suppliers and wholesalers

Details about this decision

In February 2018, PHARMAC issued a Request for Proposal (“RFP”) for haemodialysis products for non-exclusive national agreements for listing on the Pharmaceutical Schedule

After completing the RFP evaluation processes, and consulting on the provisional Agreement reached with Baxter, PHARMAC has decided to list Baxter’s medical devices in Part III of Section H of the Pharmaceutical Schedule from 1 August 2020.

The list of products will be available of PHARMAC’s website from 1 August 2020, in both a PDF document and an Excel spreadsheet

DHBs can continue to choose which haemodialysis products they purchase, including those from other suppliers. DHBs that purchase haemodialysis products from Baxter must do so under the terms and conditions, including pricing, in the Agreement, from 1 August 2020.

The Agreement includes terms and conditions for training and education to be provided by Baxter on the appropriate use of its products, which is to be provided at times as agreed with individual DHBs.

Our response to what you told us

We appreciate the time people took to respond to this consultation.

A summary of the main themes raised in feedback and our responses to the feedback are set out below:

Theme

Comment

Products currently purchased from supplier were missing from the proposed device listings.

These products have now been included and updated. 

Commercial calculation tool does not allow for all products and support to be included.

The tools have been updated in both products and format to allow greater flexibility.

The commercial tools used are a useful addition.

Noted.

If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.